Illumina, Inc. (ILMN) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
"main_header": {
"sid": 1155858,
"name": "Illumina, Inc.",
"stock_name": "Illumina, Inc.",
"full_name": "Illumina, Inc.",
"name_url": "stocks-analysis/illumina-inc",
"exchange": 210,
"exchangecode": "NAS",
"country_id": 2,
"currency": "USD",
"cmp": "128.03",
"chg": 0.48,
"chgp": "0.38%",
"dir": 1,
"prev_price": "127.55",
"mcapval": "18,919.29",
"mcap": "Small Cap",
"scripcode": "",
"symbol": "",
"ind_name": "Pharmaceuticals & Biotechnology",
"ind_code": 2320,
"indexname": "S&P 500",
"isin": "US4523271090",
"curr_date": "Dec 04",
"curr_time": "",
"bse_nse_vol": "1.9 M",
"exc_status": "Active",
"traded_date": "Dec 04, 2025",
"traded_date_str": "2025 12 04",
"score": "",
"scoreText": "",
"Live": 0,
"market_time": 0,
"is_blur": 1,
"is_blur_class": "blur-registerF-score-header",
"is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/illumina-inc-1155858-210&utm_source=Spage_Header_Score",
"mojoone": {
"ismore": 0
}
},
"news": {
"results": [
{
"title": "Is Illumina, Inc. technically bullish or bearish?",
"link": "https://www.marketsmojo.com/news/stocks-in-action/is-illumina-inc-technically-bullish-or-bearish-3673619",
"imagepath": "",
"date": "2025-11-05 11:21:08",
"description": "As of 31 October 2025, the technical trend for Illumina, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, and the moving averages indicate a bullish stance on the daily timeframe. Additionally, the Bollinger Bands and Dow Theory both reflect a mildly bullish outlook on both weekly and monthly timeframes. However, the KST shows a mildly bearish signal on the weekly and bearish on the monthly, which tempers the overall bullish sentiment.\n\nIn terms of performance, Illumina has underperformed the S&P 500 across multiple periods, with a year-to-date return of -12.55% compared to the S&P 500's 16.30%, and a one-year return of -21.97% versus the S&P 500's 19.89%. Overall, the current technical stance is mildly bullish, but caution is warranted due to mixed signals from some indicators...."
},
{
"title": "Is Illumina, Inc. overvalued or undervalued?",
"link": "https://www.marketsmojo.com/news/stocks-in-action/is-illumina-inc-overvalued-or-undervalued-3673387",
"imagepath": "",
"date": "2025-11-05 11:10:27",
"description": "As of 31 October 2025, the valuation grade for Illumina, Inc. has moved from fair to expensive, indicating that the company is currently overvalued. Key valuation ratios include a P/E ratio of 26, a Price to Book Value of 6.89, and an EV to EBITDA of 9.89, all of which suggest that the stock is trading at a premium compared to its peers. For instance, Biogen, Inc. has a P/E ratio of 13.57, highlighting a significant disparity in valuation between the two companies.\n\nFurthermore, Illumina's PEG ratio stands at an exceptionally low 0.07, which typically indicates a potential undervaluation based on growth expectations; however, the overall high valuation metrics suggest otherwise. In terms of recent performance, Illumina has underperformed against the S&P 500, with a year-to-date return of -12.55% compared to the index's 16.30%. This trend of underperformance over multiple periods reinforces the conclusion th..."
},
{
"title": "Is Illumina, Inc. technically bullish or bearish?",
"link": "https://www.marketsmojo.com/news/stocks-in-action/is-illumina-inc-technically-bullish-or-bearish-3670806",
"imagepath": "",
"date": "2025-11-04 11:32:36",
"description": "As of 31 October 2025, the technical trend for Illumina, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, and the monthly MACD is mildly bullish, supporting the positive outlook. Additionally, the Bollinger Bands indicate a mildly bullish stance on both weekly and monthly time frames. The daily moving averages are bullish, further reinforcing the upward momentum. However, the KST shows a mildly bearish signal on the weekly and bearish on the monthly, which introduces some caution. Dow Theory also supports a mildly bullish view on both time frames.\n\nIn terms of performance, Illumina's stock has returned 19.57% over the past week and 17.50% over the past month, significantly outperforming the S&P 500, which returned 0.71% and 1.92% respectively. However, the longer-term returns are concerning, with a year-to-date return of -10.21% and a one-year return of -19.88%, both under..."
},
{
"title": "Is Illumina, Inc. overvalued or undervalued?",
"link": "https://www.marketsmojo.com/news/stocks-in-action/is-illumina-inc-overvalued-or-undervalued-3670579",
"imagepath": "",
"date": "2025-11-04 11:16:23",
"description": "As of 31 October 2025, Illumina, Inc. has moved from fair to expensive, indicating a shift in its valuation grade. The company appears overvalued, with a P/E ratio of 26, significantly higher than its peer BioMarin Pharmaceutical, Inc. at 15.17 and Elanco Animal Health, Inc. at 19.25. Additionally, the EV to EBITDA ratio stands at 9.89, which is also above the industry average, suggesting that the stock may not be justified at its current price level.\n\nIn terms of performance, Illumina's returns have lagged behind the S&P 500, with a year-to-date return of -10.21% compared to the index's 16.30%, and a 5-year return of -58.38% versus 109.18% for the S&P 500. These figures reinforce the notion that Illumina is overvalued relative to its peers and the broader market...."
},
{
"title": "Illumina Stock Soars 24.78%, Hits Intraday High of $123.91",
"link": "https://www.marketsmojo.com/news/stocks-in-action/illumina-stock-soars-2478-hits-intraday-high-of-12391-3667366",
"imagepath": "https://i.marketsmojo.com/newsimg/2025/11/IlluminaInc_priceRelatedfactors_3667366.png",
"date": "2025-11-03 17:38:48",
"description": "Illumina, Inc. has seen notable stock activity, with a significant intraday high and a strong weekly performance. Despite recent challenges reflected in longer-term returns, the company reported impressive net profit growth and maintains a low debt-to-equity ratio, indicating a solid financial position amidst market fluctuations."
},
{
"title": "Illumina, Inc. Experiences Valuation Adjustment Amid Competitive Market Landscape",
"link": "https://www.marketsmojo.com/news/stocks-in-action/illuminas-valuation-grade-changes-from-fair-to-expensive-amid-stock-price-surge-3667056",
"imagepath": "https://i.marketsmojo.com/newsimg/2025/11/IlluminaInc_valuationdot_3667056.png",
"date": "2025-11-03 15:43:02",
"description": "Illumina, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 26 and a Price to Book Value of 6.89. The company demonstrates strong operational efficiency with an EV to EBIT of 12.09 and a ROCE of 44.33%, reflecting its competitive position in the Pharmaceuticals & Biotechnology sector."
},
{
"title": "Is Illumina, Inc. technically bullish or bearish?",
"link": "https://www.marketsmojo.com/news/stocks-in-action/is-illumina-inc-technically-bullish-or-bearish-3666403",
"imagepath": "",
"date": "2025-11-03 11:32:01",
"description": "As of 31 October 2025, the technical trend for Illumina, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, and the monthly MACD is mildly bullish, supporting the positive trend. Additionally, Bollinger Bands are bullish on both weekly and monthly time frames. Daily moving averages also indicate a bullish stance. However, the KST is mildly bearish weekly and bearish monthly, while the OBV shows a mildly bearish weekly trend with no trend monthly. \n\nIn terms of performance, Illumina has outperformed the S&P 500 over the past week and month, returning 23.40% and 20.81% respectively, but has underperformed significantly year-to-date and over longer periods. Overall, the current technical stance is mildly bullish, driven primarily by the bullish MACD and Bollinger Bands...."
},
{
"title": "Is Illumina, Inc. overvalued or undervalued?",
"link": "https://www.marketsmojo.com/news/stocks-in-action/is-illumina-inc-overvalued-or-undervalued-3666147",
"imagepath": "",
"date": "2025-11-03 11:15:40",
"description": "As of 31 October 2025, Illumina, Inc. has moved from fair to expensive in its valuation grade. The company appears overvalued, particularly when considering its P/E ratio of 26, which is significantly higher than the peer average of 19.09 for similar companies in the industry. Additionally, the EV to EBITDA ratio stands at 9.89, again above the peer average of 13.83, indicating a premium valuation compared to its peers. The PEG ratio is notably low at 0.07, suggesting that growth expectations may not justify the current price.\n\nIn the peer comparison, BioMarin Pharmaceutical, Inc. is valued fairly with a P/E of 15.17, while Elanco Animal Health, Inc. is also expensive with a P/E of 19.25. This further emphasizes Illumina's elevated valuation relative to its industry counterparts. Over the past year, Illumina's stock has returned -14.29%, underperforming the S&P 500's return of 19.89%, reinforcing the notion..."
},
{
"title": "Is Illumina, Inc. technically bullish or bearish?",
"link": "https://www.marketsmojo.com/news/stocks-in-action/is-illumina-inc-technically-bullish-or-bearish-3664518",
"imagepath": "",
"date": "2025-11-02 11:17:20",
"description": "As of 31 October 2025, the technical trend for Illumina, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, and the monthly MACD is mildly bullish, supporting the positive shift. Bollinger Bands are bullish on both weekly and monthly time frames, and daily moving averages are also bullish. However, the KST is mildly bearish on the weekly and bearish on the monthly, while the OBV shows a mildly bearish stance on the weekly and no trend on the monthly. The Dow Theory indicates a mildly bullish trend on the weekly but no trend on the monthly.\n\nIn terms of performance, Illumina has outperformed the S&P 500 over the past week and month, returning 23.40% and 20.81% respectively, while the S&P 500 returned only 0.71% and 1.92%. However, over longer periods, Illumina has significantly underperformed the benchmark, with a year-to-date return of -7.55% compared to the S&P 500's 16.30%..."
}
],
"total": 29,
"sid": "1155858",
"stock_news_url": "https://www.marketsmojo.com/news/illumina-inc-1155858"
},
"announcements": "",
"corporate_actions": {
"msg": "No corporate action Found"
}
}

News and Views

Is Illumina, Inc. technically bullish or bearish?

2025-11-05 11:21:08

As of 31 October 2025, the technical trend for Illumina, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, and the moving averages indicate a bullish stance on the daily timeframe. Additionally, the Bollinger Bands and Dow Theory both reflect a mildly bullish outlook on both weekly and monthly timeframes. However, the KST shows a mildly bearish signal on the weekly and bearish on the monthly, which tempers the overall bullish sentiment. In terms of performance, Illumina has underperformed the S&P 500 across multiple periods, with a year-to-date return of -12.55% compared to the S&P 500's 16.30%, and a one-year return of -21.97% versus the S&P 500's 19.89%. Overall, the current technical stance is mildly bullish, but caution is warranted due to mixed signals from some indicators....

Is Illumina, Inc. overvalued or undervalued?

2025-11-05 11:10:27

As of 31 October 2025, the valuation grade for Illumina, Inc. has moved from fair to expensive, indicating that the company is currently overvalued. Key valuation ratios include a P/E ratio of 26, a Price to Book Value of 6.89, and an EV to EBITDA of 9.89, all of which suggest that the stock is trading at a premium compared to its peers. For instance, Biogen, Inc. has a P/E ratio of 13.57, highlighting a significant disparity in valuation between the two companies. Furthermore, Illumina's PEG ratio stands at an exceptionally low 0.07, which typically indicates a potential undervaluation based on growth expectations; however, the overall high valuation metrics suggest otherwise. In terms of recent performance, Illumina has underperformed against the S&P 500, with a year-to-date return of -12.55% compared to the index's 16.30%. This trend of underperformance over multiple periods reinforces the conclusion th...

Is Illumina, Inc. technically bullish or bearish?

2025-11-04 11:32:36

As of 31 October 2025, the technical trend for Illumina, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, and the monthly MACD is mildly bullish, supporting the positive outlook. Additionally, the Bollinger Bands indicate a mildly bullish stance on both weekly and monthly time frames. The daily moving averages are bullish, further reinforcing the upward momentum. However, the KST shows a mildly bearish signal on the weekly and bearish on the monthly, which introduces some caution. Dow Theory also supports a mildly bullish view on both time frames. In terms of performance, Illumina's stock has returned 19.57% over the past week and 17.50% over the past month, significantly outperforming the S&P 500, which returned 0.71% and 1.92% respectively. However, the longer-term returns are concerning, with a year-to-date return of -10.21% and a one-year return of -19.88%, both under...

Is Illumina, Inc. overvalued or undervalued?

2025-11-04 11:16:23

As of 31 October 2025, Illumina, Inc. has moved from fair to expensive, indicating a shift in its valuation grade. The company appears overvalued, with a P/E ratio of 26, significantly higher than its peer BioMarin Pharmaceutical, Inc. at 15.17 and Elanco Animal Health, Inc. at 19.25. Additionally, the EV to EBITDA ratio stands at 9.89, which is also above the industry average, suggesting that the stock may not be justified at its current price level. In terms of performance, Illumina's returns have lagged behind the S&P 500, with a year-to-date return of -10.21% compared to the index's 16.30%, and a 5-year return of -58.38% versus 109.18% for the S&P 500. These figures reinforce the notion that Illumina is overvalued relative to its peers and the broader market....

Illumina Stock Soars 24.78%, Hits Intraday High of $123.91

2025-11-03 17:38:48

Illumina, Inc. has seen notable stock activity, with a significant intraday high and a strong weekly performance. Despite recent challenges reflected in longer-term returns, the company reported impressive net profit growth and maintains a low debt-to-equity ratio, indicating a solid financial position amidst market fluctuations.

Illumina, Inc. Experiences Valuation Adjustment Amid Competitive Market Landscape

2025-11-03 15:43:02

Illumina, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 26 and a Price to Book Value of 6.89. The company demonstrates strong operational efficiency with an EV to EBIT of 12.09 and a ROCE of 44.33%, reflecting its competitive position in the Pharmaceuticals & Biotechnology sector.

Is Illumina, Inc. technically bullish or bearish?

2025-11-03 11:32:01

As of 31 October 2025, the technical trend for Illumina, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, and the monthly MACD is mildly bullish, supporting the positive trend. Additionally, Bollinger Bands are bullish on both weekly and monthly time frames. Daily moving averages also indicate a bullish stance. However, the KST is mildly bearish weekly and bearish monthly, while the OBV shows a mildly bearish weekly trend with no trend monthly. In terms of performance, Illumina has outperformed the S&P 500 over the past week and month, returning 23.40% and 20.81% respectively, but has underperformed significantly year-to-date and over longer periods. Overall, the current technical stance is mildly bullish, driven primarily by the bullish MACD and Bollinger Bands....

Is Illumina, Inc. overvalued or undervalued?

2025-11-03 11:15:40

As of 31 October 2025, Illumina, Inc. has moved from fair to expensive in its valuation grade. The company appears overvalued, particularly when considering its P/E ratio of 26, which is significantly higher than the peer average of 19.09 for similar companies in the industry. Additionally, the EV to EBITDA ratio stands at 9.89, again above the peer average of 13.83, indicating a premium valuation compared to its peers. The PEG ratio is notably low at 0.07, suggesting that growth expectations may not justify the current price. In the peer comparison, BioMarin Pharmaceutical, Inc. is valued fairly with a P/E of 15.17, while Elanco Animal Health, Inc. is also expensive with a P/E of 19.25. This further emphasizes Illumina's elevated valuation relative to its industry counterparts. Over the past year, Illumina's stock has returned -14.29%, underperforming the S&P 500's return of 19.89%, reinforcing the notion...

Is Illumina, Inc. technically bullish or bearish?

2025-11-02 11:17:20

As of 31 October 2025, the technical trend for Illumina, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, and the monthly MACD is mildly bullish, supporting the positive shift. Bollinger Bands are bullish on both weekly and monthly time frames, and daily moving averages are also bullish. However, the KST is mildly bearish on the weekly and bearish on the monthly, while the OBV shows a mildly bearish stance on the weekly and no trend on the monthly. The Dow Theory indicates a mildly bullish trend on the weekly but no trend on the monthly. In terms of performance, Illumina has outperformed the S&P 500 over the past week and month, returning 23.40% and 20.81% respectively, while the S&P 500 returned only 0.71% and 1.92%. However, over longer periods, Illumina has significantly underperformed the benchmark, with a year-to-date return of -7.55% compared to the S&P 500's 16.30%...

View All News